About Nagoya University Hospital

About Nagoya University Hospital


Message from the Director


Thank you for visiting the Nagoya University Hospital homepage.

Nagoya University Hospital was established in 1871 (Meiji 4) as a temporary public hospital at the former site of the Nagoya Domain conference chamber. With understanding and support from the local community, it has developed into the highly-respected institution it is today. Currently, it leads the region, providing cutting-edge medical care that meets global standards.
As part of this initiative, Nagoya University Hospital has introduced IoT to provide better quality and safer healthcare in a "smart hospital" setting. In January 2018, when the Central Consultation Building B became operational, computer facilities were also augmented, allowing the start of centralized management of electronic medical chart data. After this initial step where medical devices such as artificial respiratory devices and electronic medical charts are connected, and patient respiration rate and pulse data are monitored in real -time, in the future, patients will use wearable devices that allow staff to monitor their physical status in real-time. By realizing a "smart hospital" system and expanding IoT to allow for rapid response and decreasing patient and healthcare staff burden, we hope to prevent medical errors. We will continue to promote a so-called IoH (Internet of Humans) to connect and improve the quality and safety of healthcare at our institution.

In February 2018, Nagoya University Hospital was designated a Core Hospital for Cancer Genome Medical Care. Traditionally, chemotherapy with anticancer drugs not only damages cancer cells, but also the healthy normal cells in the vicinity, and adverse drug reactions are a major issue. In cancer genome medicine however, patient cancer cells are tested to determine the gene mutations to identify drugs that pinpoint those specific mutations which are then administered. Although efficiency is improved with fewer adverse drug reactions, some unexpected genetic information may be revealed through the use of these tests. At our institution, we have a genetic counselor available to cover all such instances. Our hospital networks with local hospitals to provide appropriate cancer genome medicine care.
We are also preparing for clinical trials of CAR-T treatment against cancer. This is a form of immunotherapy that uses genetically-modified immune cells and it is potentially a last resort against acute lymphocytic leukemia (ALL). Currently, our hospital is planning to start clinical studies of CAR-T in ALL, but depending on how well the development of immunotherapy proceeds, it may be prove useful against a wide range of cancers. After verifying the efficacy during the clinical study, we hope to expand the indications to cover other cancers.

We will continue to take steps to advance globalization of healthcare. For Nagoya University Hospital to be recognized internationally, we must ensure that both the quality of healthcare and patient safety are maintained at global standards. We are preparing for Joint Commission International (JCI) accreditation and expect to undergo review at the end of this fiscal year.
As a teaching hospital, our priorities are to maintain a warm humanity along with state-of-the-art technology. Good healthcare should not only be easy to accept, but all technology in healthcare must be cutting-edge in order to instill a deep trust in our institution. It would otherwise be impossible for us to fulfill the expectations of our patients who come from within Japan and abroad to be treated. Our goal is to remain a hospital where patients feel ensured that "The future is here."

We appreciate your continued support and encouragement.

Naoki ISHIGURO, M.D., Ph.D.
Director, Nagoya University Hospital

As of July 1st, 2018